You are here: Home » PTI Stories » National » News
Business Standard

New single-dose Ebola drug treatment developed

Press Trust of India  |  Houston 

Scientists have developed an experimental drug that in one dose successfully protected nonhuman primates against a of all strains of the deadly

from The in the US said that previous therapeutics typically were of the "one bug, one drug" variety.

However, because of the unpredictable nature and variety of the virus, scientists have been seeking a way to protect against different strains of the

"Our experimental drug can protect against all forms of known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," said Geisbert.

The study, published in the journal Cell Host & Microbe, found that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal infections caused by the Bundibugyo and strain as well as the deadliest Zaire strain that caused the 2013-16 epidemic in and the current outbreak in the

"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, of US-based

"Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions," Zeitlin said.

"The ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure" he said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, January 10 2019. 11:30 IST